Process Approach to Detecting Early Cognitive Impairment Rhoda Au, Ph.D., Friday Harbor 9/14/15 MBA.

Slides:



Advertisements
Similar presentations
Clinical Phenomenology and Neuroimaging Correlates in ALS-FTD
Advertisements

Mini-Mental State Examination - 2nd Edition
Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.
Department of Neurology, Mayo Clinic Arizona
The Brief Cognitive Assessment Tool (BCAT): A New Test Emphasizing Contextual Memory and Executive Functions Drs. William Mansbach, Elizabeth MacDougall,
MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.
VAMC St Louis University Mental Status Examination - SLUMS
Neurocognitive Manifestations in ME/CFS Gudrun Lange, PhD Professor Department of Physical Medicine and Rehabilitation, Rutgers-NJMS.
Neuropathology and Cognitive Scores Workgroup The role of vascular and Alzheimer’s Disease pathology in differential cognitive impairment among older adults.
Including Cognitive Disabilities in International Standards David Fourney Department of Computer Science, University of Saskatchewan, Saskatoon, Saskatchewan,
ADNI 3 Clinical Core Plans
Signed Paired Associates Test (SPAT). SPAT Structure Similar to WMS “paired associates” subtest 14 sign pairs – 7 easy & 7 hard Based on sign associate.
Neuropsychological Testing Neuropsychological Testing, Continued: Multi-dimensional assessment.
The New Brief Cognitive Assessment Tool (BCAT): The Role of Cognitive Assessment in Improving Health Outcomes Dr. William Mansbach October 25, 2011.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Alexander I. Tröster, Ph.D. Department of Neurology
Mild Cognitive Impairment
ACT on Alzheimer’s Disease Curriculum Module VI: Screening.
ACT on Alzheimer’s Disease Curriculum Module VII: Disease Diagnosis.
MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.
Neuropsychological Assessment. 1) Mental Activity-Attention and speed of information processing Filtering, focusing, shifting tracking Filtering, focusing,
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
Epidemiology of Dementia: the MoVIES Project Alzheimer’s Disease Patient Registry (ADPR ), University of Pittsburgh Initially funded by NIA under.
Canadian Study of Health and Aging Methodological Contributions of the CSHA.
ACT on Alzheimer’s Disease Curriculum Module V: Cognitive Assessment and the Value of Early Identification.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
MEMORY ASSESSMENT in the LAB vs. the CLINIC
Procedures Manual, Control Series, & Phenotype Committee Update Stephanie Doan, MPH NIA AD Genetics Initiative Co-Coordinator Columbia University.
COGNITIVE TESTING and THE IMPACT OF TESTING
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Neuropsychological Testing. Purposes of Neuropsych Testing  Determination of brain damage  Localization of brain lesions  Determination of functional.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Classification of Patients with Mild Cognitive Impairment vs. Normal Controls based on Experimental and Conventional Standardized Measures of Processing.
Friday Harbor Psychometrics 2012 Scientific Summary UC Davis / SENAS (Spanish and English Neuropsychological Assessment Scales)
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
Alabama Brief Cognitive Screener (ABCs)
Clinical, cognitive and genetic predictors of conversion from amnestic mild cognitive impairment to Alzheimer’s disease in Chinese older adults (Chu LW,
Identifying and Tracking Changes in Cognition Related to NPH Sheldon Herring, Ph.D. Clinical Director Outpatient Brain Injury and Young Stroke Program.
Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.
Mild Cognitive Impairment, Activity Participation, Functional Difficulty, and Adaptations in Functionally Vulnerable Elderly People: A Closer Look Laraine.
The diagnosis of dementia - 2
Were Prior Mild TBI Meta-Analytic Results Refuted or Replicated? Martin L. Rohling, Ph.D.Laurence Binder, Ph.D. U. of South AlabamaOregon Health Sciences.
All Hands Meeting 2004 Ontologies for Data Mediation Christine Fennema-Notestine, Ph.D.
Copyright © 2016 American Medical Association. All rights reserved.
Laura Baker, PhD Internal Medicine, Neurology, & Public Health Sciences Wake Forest School of Medicine Winston-Salem, NC USA.
Friday Harbor Laboratory University of Washington August 22-26, 2005
Lorna Myers, Ph.D. Director of Clinical Neuropsychology
Experiments: Part 2.
Applications to AD with Sample SAS Codes
Epidemiology of Dementia: the MoVIES Project
Dwight Dickinson1, Evan Giangrande1, Daniel R. Weinberger2, Karen F
Suboptimal Performance: When Do Methods & Mood Matter?
Paul K. Crane, MD MPH Dan M. Mungas, PhD
Imaging AD Progression Amyloid Imaging Agents.
Growth Models Oklahoma
Designed for individuals ages 16 and older.
Nat. Rev. Neurol. doi: /nrneurol
Early Cognitive Decline and the Aging Brain - Overview
چون آن مرغی که درهر برگ گل نقش خزان بیند
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
New FDA Guidance on Early Alzheimer’s Disease
Experiments: Part 2.
Spanish and English Neuropsychological Assessment Scales - Guiding Principles and Evolution Friday Harbor Psychometrics Workshop 2005.
Friday Harbor Laboratory University of Washington August 27-31, 2006
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Dementia GEC Faculty Scholars Program
Statistically-Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile AnalysiS.
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Presentation transcript:

Process Approach to Detecting Early Cognitive Impairment Rhoda Au, Ph.D., Friday Harbor 9/14/15 MBA

Objectives Understanding of full scope of FHS cognitive data Understanding of full scope of FHS cognitive data How neuropsychological tests are a richer resource than they are typically used How neuropsychological tests are a richer resource than they are typically used Preview of things to come Preview of things to come

Framingham Heart Study Dementia Study – Prevalence: Gen 1 Original cohort Baseline NP 1984 NINDS-ADRDA AD Diagnostic Criteria 1981 MMSE

Cogniitve Measures – Gen 1 - Exam 14/15 WMS Logical Memory – IR & DR WMS Visual Reproductions - IR WMS Paired Associates - IR WMS Digit Span WAIS Similarities Controlled Word Association Test - FAS

Framingham Heart Study Dementia Incidence – Add Gen 2 Offspring cohort Baseline NP 1984 NINDS-ADRDA AD Diagnostic Criteria 1981 MMSE 1991 MMSE 1971 Gen 1 Gen 2

Framingham Heart Study Incident Dementia + Pre-Clinical Baseline NP 1984 NINDS-ADRDA AD Diagnostic Criteria 1981 MMSE 1999 Brain MRI/NP (n= 2617) MMSE 1999 Brain MRI/NP (n= 331) Gen 2 Gen 1

Cognitive Tests Gen 1 – Exams Gen 2 – Exam 7 WMS Logical Memory – IR & DR WMS Visual Reproductions – IR & DR WMS Paired Associates – IR & DR WAIS Similarities Digit Span Controlled Word Association Test – FAS Trails A & B Boston Naming Test – 30 Item Hooper Visual Organization Test Finger Tapping WRAT III Reading Subtest

Mild Cognitive Impairment 1999: Preclinical AD 2004: Amnestic Memory Only – Verbal and/or Visual Memory + Other Cognitive Domains Non-Amnestic Single Domain Multiple Domains

Cognitive Impairment Detection Challenge: FHS Current Two-Method Approach The Traditional Approach The Traditional Approach Boston Process Approach Boston Process Approach –Preserve traditional measures –Expand test beyond single score –Focus on path to final response Value of incorrect responses Value of incorrect responses

Cognitive Tests – Gen 1 – Exam 28 Gen 2 – Exam 8 WMS Logical Memory – IR & DR & Recogn WMS Visual Reproductions – IR & DR & Recogn WMS Paired Associates – IR & DR & Recogn WAIS Similarities Digit Span Controlled Word Association Test – FAS Category Fluency - Animals Trails A & B Boston Naming Test – 30 Item Hooper Visual Organization Test Finger Tapping WRAT III Reading Subtest Clock Drawing Test WISC-III Math Fluency Digit Symbol Substitution Test

Quantitative vs. Qualitative: LM –IR Traditional scores Total verbatim Total paraphrase Total – V+P Qualitative Scores Confabulations related Intrusions related Confabulations unrelated Intrusions unrelated Total Number of Qualitative Measures = 10

Quantitative vs. Qualitative: LM –DR Qualitative measures from IR PLUS: Confabulations Related & Unrelated from IR Related & Unrelated - New Intrusions Related & Unrelated from IR Related & Unrelated - New Total Number of Qualitative Measures = 14

Digit Span – Qualitative Errors Differentiate between sequencing and non-sequencing errors Sequencing Error example: For 1 – 5 – 2 – 8 – 6, participant responds 6 – 8 – 2 – 1 – 5 Non-sequencing Error examples: For 1 – 5 – 2 – 8 – 6, participant responds 6 – 8 – 2 – 5 For 1 – 5 – 2 – 8 – 6, participant responds 6 – 3 – 2 – 1 – 5

Digit Span – Limit Testing Digit Span – Limit Testing Testing the limits Testing the limits S TANDARD D ISCONTINUE T ESTING THE L IMITS A CTUAL D ISCONTINUE

Digit Span Calculating Qualitative Scores Calculate total score accounting for continuum of error types 1) Score each trial [0, 1, or 2] 2) Assign qualitative value for each digit span [scale 0 to 5] 3) Sum qualitative values for qualitative total score

Digit Span – Scoring Trials TRIAL SCORING: - 2 = correct response - 1 = incorrect response (sequencing error) - 0 = incorrect response (non- sequencing error) - 8 = not administered

Digit Span – Scoring Spans SPAN SCORING: TRIAL #1 TRIAL #2 QUALITATIVE SCORE

Qualitative errors – Trails B Perceptual Errors Other Errors Pen lifts Starts before told to begin Self-corrected & Examiner-corrected

TIME TO COMPLETION: 2:16TIME TO COMPLETION: 2:15 Examiner-corrected Errors: 4 Self-corrected Errors: 0 Examiner-corrected Errors: 1 Self-corrected Errors: 1 Pen lifts: 9

Qualitative errors Verbal fluency FAS Wrong first letter Broken rules Perseverations ANIMALS Broken rules Perseverations

Verbal Fluency

Category Fluency - Animals 64-year old woman 64-year old woman –Quantitative- 15 responses –Qualitative- 0 errors 62-year old man 62-year old man –Quantitative- 15 responses –Qualitative- 3 errors

Logical memory - # perseverations: IR & DR Visual Reproductions – perseverations (Y/N per design: IR & DR Paired Associates – perseveration/pair: IR Similarities – perseveration/item FAS - # of perseverations/trial Animals - # of perseverations BNT – perseveration/item Process Across Tests: Executive Function - Perseverations Across Tests

Framingham Heart Study Incident Dementia + Pre-Clinical + Asymptomatic Gen Baseline NP 1984 NINDS-ADRDA AD Diagnostic Criteria 1981 MMSE 1999 Brain MRI/NP Gen MMSE 1999 Brain MRI/NP 2020 Gen Brain MRI w/ DTI +NP Repeat NP/MRI Repeat NP/MRI Repeat NP/MRI

What is Pre-clinical? 65+ years old 65+ years old –Measures differentiate cognitively intact vs. clinically demented years old years old –Measures differentiate cognitively intact vs. pre-clinical <45 years old <45 years old –Measures differentiate cognitively intact vs. cognitively intact

Adapted by Drs. Dana Penney and Randall Davis from Fig 3 of Criteria For Preclinical Alzheimer’s Disease, Alzheimer’s Association report (2010), which in turn cites Jack C R, et al., Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade, The Lancet, 9:1, Jan 2010, pp Cognitive Impairment Detection Challenge: When Can It Be Detected?

BPA on Steroids Digital Clock Drawing Test

e-NP Platform

FHS Cognitive Data Today Initial BPA data collection in Gen 3 ( ) Initial BPA data collection in Gen 3 ( ) Repeat BPA data collection in Gen 2 ( ) Repeat BPA data collection in Gen 2 ( ) Repeat BPA in Gen 3 ( ) Repeat BPA in Gen 3 ( ) Digital Ink technology ( ) Digital Ink technology ( ) e-NP Platform (2016 – 2020) e-NP Platform (2016 – 2020)